Dr. Hamilton on the Utility of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer


In Partnership With:

Erika P. Hamilton, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the utility of CDK4/6 inhibitors in hormone receptor (HR)–positive, HER2-negative breast cancer.

It is important to determine which patients are most likely to benefit from different treatments in HR-positive breast cancer, Hamilton says. At the 2021 ESMO Congress, updated data from the phase 3 MONALEESA-2 trial (NCT01958021) were presented, demonstrating an encouraging improvement in overall survival with the CDK4/6 inhibitor ribociclib (Kisqali) plus letrozole vs placebo plus letrozole in postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer , Hamilton adds. 

Overall, these data are practice affirming and indicate that postmenopausal patients with HR-positive, HER2-negative disease should be offered CDK4/6 inhibitors in the frontline setting, Hamilton continues. Beyond CDK4/6 inhibitors, further treatment refinement is needed to optimize options for patients with PIK3CA or ESR1 alterations. Novel oral selective estrogen receptor degraders are emerging as a potential strategy for these patients; however, it is important to continue parsing out what treatments are best suited for individual patients, Hamilton concludes.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS